• 6 November 2005
    Baxter and Kuros announce product license and collaboration agreement

    Subsidiaries of Baxter International Inc. and Kuros Biosurgery AG announced that they have signed an agreement under which Kuros has granted Baxter exclusive worldwide rights to develop and commercialize a portfolio of hard and soft tissue-repair products. These products will be based on Baxter’s fibrin-based biomatrix, TISSEEL® Fibrin Sealant, combined with Kuros’ proprietary biologics and associated binding technology.

    The two companies, working together under a long-term research and development agreement, have shown that Baxter’s TISSEEL, combined with Kuros’ novel biologics and fibrin-based binding technology, enables growth factors and other bioactive agents to be attached to fibrin, thereby enhancing the regeneration of bone and soft tissue.

    “We signed this commercialization agreement based on the pre-clinical results from our original research collaboration with Kuros, which showed that Baxter’s TISSEEL combined with Kuros’ biologics has promise in enhancing the regeneration of bone and soft tissue,” said Joy Amundson, president, Baxter’s BioScience business. “This agreement positions our BioSurgery business to enter the fast-growing orthobiologic market. In addition, the products developed under this agreement complement our current product portfolio and build on our strategy to develop surgical therapies for tissue and bone regeneration.”

    “Our long-term R&D agreement with Baxter has focused on combining our novel biologics and associated fibrin-binding technology and Baxter’s proprietary TISSEEL. This new agreement is a major accreditation of both companies’ product development work and capabilities,” said Didier Cowling, president & CEO, Kuros. “We are pleased to be working with Baxter, recognizing its current position in the surgical marketplace.”

    Under the terms of the agreement, Kuros will receive upfront and milestone payments, as well as royalties on global product sales. Kuros and Baxter will continue to collaborate through successful Phase II clinical trials. Baxter will manage Phase III clinical development and regulatory licensing. No other terms of the agreement were disclosed. About Baxter

    Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter assists healthcare professionals and their patients with treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices,pharmaceuticals and biotechnology to make a meaningful difference in patients ́ lives. For more information about Baxter, please visit About Kuros Biosurgery AG

    Kuros is a biomedical company focused on developing novel injectable biologics and biomaterials for localized therapy. Through its expertise in advanced biomaterials, bioactives and their combination, Kuros is bringing innovative products to market to repair and regenerate injured or diseased tissues. For more information visit Kuros at

    ## #

    This release includes forward-looking statements concerning the company's collaboration with Kuros and future product development involving biomaterials, including the development of the market for such materials. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: successful clinical development of the product through its early stages, as well as Phase II and III clinical trials; receipt of necessary regulatory approvals; market acceptance of the product; and other risks identified in the company’s most recent filing on Form 10-Q. The company does not undertake to update its forward-looking statements.